Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07028749 · ClinicalTrials.gov registry record · Phase 2
Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
A Phase 2 study of Hypertriglyceridemia, sponsored by Marea Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 216
- Enrollment target
- 20
- Study locations
NCT07028749: Active Phase 2 study of Hypertriglyceridemia, sponsored by Marea Therapeutics.
NCT07028749 is a Phase 2 study of Hypertriglyceridemia that is active but no longer recruiting, run by Marea Therapeutics. The registered enrollment target is 216 participants, above the 168-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (29% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07028749, a Phase 2 study of Hypertriglyceridemia, is active but no longer recruiting, sponsored by Marea Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 216 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to evaluate the effect of MAR001 compared to placebo on levels of the TG and RC in adults with elevated TG and RC.
Primary Outcome
Percent change from baseline at Week 12 in fasting TG compared to placebo
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MAR001
Study Locations (20)
Alabama
- Marea Site 328 - Anniston
- Marea Site 329 - Mobile
Florida
- Marea Site 302 - Boca Raton
- Marea Site 307 - Port Saint Lucie
Georgia
- Marea Site 310 - Columbus
- Marea Site 319 - Peachtree Corners
Illinois
- Marea Site 317 - Park Ridge
- Marea Site 325 - Springfield
Missouri
- Marea Site 330 - Kansas City
- Marea Site 305 - St Louis
New York
- Marea Site 304 - Great Neck
- Marea Site 318 - New Windsor
North Carolina
- Marea Site 303 - Greensboro
- Marea Site 315 - Winston-Salem
South Carolina
- Marea Site 314 - Greenville
- Marea Site 320 - Little River
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2025-06-30 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT07028749 still lists
NCT07028749 is an interventional study that assigns participants to a tested intervention. The registered 216 participants enrollment target is mid-sized for trials with a published cap, above the 168-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (29% higher).
The record links to 1 condition, with Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07028749 names 20 study sites across 12 states, led by Alabama, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT07028749 about?
NCT07028749 is a clinical study titled "Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol". The primary objective of the study is to evaluate the effect of MAR001 compared to placebo on levels of the TG and RC in adults with elevated TG and RC.
What is the current status of trial NCT07028749?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 216 participants. The study started on 2025-06-30. Estimated completion is 2026-12.
What conditions does trial NCT07028749 study?
This clinical trial studies the following conditions: Hypertriglyceridemia.
What interventions are being tested in trial NCT07028749?
The interventions under investigation include: Placebo (DRUG), MAR001 (DRUG).
Who is sponsoring clinical trial NCT07028749?
This trial is sponsored by Marea Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07028749 being conducted?
This trial has 20 study locations across Alabama, Arkansas, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertriglyceridemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07028749's enrollment target sits among peer trials
216 4th of 25 higher than 22 of 25 other Hypertriglyceridemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertriglyceridemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
RECRUITING · Phase 2
-
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 2
-
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
COMPLETED · Phase 2
-
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
COMPLETED · Phase 2
-
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
RECRUITING · Phase 3
-
Differential Thrombogenesis by EPA and DHA Mediated by HDL
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02609685 · 216 participants · NA
Active Surveillance of Papillary Thyroid Microcarcinoma
- NCT04994873 · 216 participants · NA
Skills to Enhance Positivity in Suicidal Youth
- NCT05264779 · 216 participants · NA
The Periviable GOALS Decision Support Tool
- NCT05434130 · 216 participants · Phase 2
Modulating Exercise Dosage to Improve Concussion Recovery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI